首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study
【24h】

Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study

机译:传统的草药可防止术后患有小肝细胞癌:随机对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND To explore the clinical efficacy of traditional herbal medicine (THM) in the prevention of disease recurrence of small hepatocellular carcinoma after surgery, a prospective randomized controlled study was conducted between October 2006 and May 2010. The results indicated that THM prevented the recurrence of SHCC with an efficacy that was superior to that of transarterial chemoembolization (TACE) during a median follow‐up of 26.61 months. METHODS The patients were followed up every 6 months, and the clinical data before October 20, 2015 were analyzed. The primary outcome measure was recurrence‐free survival (RFS), and the secondary outcome measure was overall survival (OS). RESULTS The 364 patients included 180 in the THM group and 184 in the TACE group. At the time of the data cutoff of October 20, 2015, a total of 205 patients demonstrated disease recurrence, including 85 patients in the THM group and 120 patients in the TACE group. The median RFS of the THM and TACE groups demonstrated a statistically significant difference ( P .001). Until October 20, 2105, there were 91 deaths, including 34 in the THM group and 57 in the TACE group. The median OS demonstrated a significant difference between the 2 groups ( P?=? .008). Multivariate analysis indicated that THM was an independent factor influencing RFS and OS. CONCLUSIONS The efficacy of THM was found to be superior to that of TACE in preventing disease recurrence in patients with small hepatocellular carcinoma and prolonging OS. Cancer 2018;124:2161‐8. ? 2018 American Cancer Society .
机译:背景技术探讨传统草药(THM)在手术后预防疾病复发性的传统草药(THM)的临床疗效,2006年10月和2010年5月之间进行了一项前瞻性随机对照研究。结果表明,THM阻止了SHCC的复发在26.61个月的中位随访期间,疗效优于龙动化疗栓塞(TACE)。方法患者每6个月进行一次,并分析2015年10月20日之前的临床资料。主要结果措施是无复发的存活率(RFS),二次结果测量是总存活(OS)。结果364名患者在THM组中包括180名,TACE集团184名。在2015年10月20日数据截止的时候,共有205名患者表现出疾病复发,包括85名患者在THM组和120例TACE组中。 THM和TACE组的中位RFS表现出统计学上的显着差异(P& .001)。直到10月20日,2105年,有91人死亡,其中34个在THM集团中,TACE集团57人。中位OS在2组之间显示出显着差异(p?=Δ.008)。多变量分析表明,THM是影响RFS和OS的独立因素。结论发现THM的疗效优于小型肝细胞癌患者疾病复发的TACE。癌症2018; 124:2161-8。还2018年美国癌症协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号